EUCTR2007-006611-23-IT进行中（未招募）1 期
Open-label, single-arm, phase II study of bevacizumab (AVASTIN) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell carcinoma - ND
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- ROCHE
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent (informed consent document to be approved by the institutions Independent Ethics Committee and consent obtained prior to any study-specific procedure) 2. Age >18 years 3. Able to comply with the protocol 4. Subject with histologically and/or cytologically confirmed, metastatic RCC, with majority (> 50%) of conventional clear-cell type is mandatory. (Subjects with predominantly papillary or sarcomatoid features, and subjects with chromophobe, oncocytoma, collecting duct tumours, Bellini tumours or transitional cell carcinoma are not allowed). Tumours of mixed histology should be categorized by the predominant cell type 5. Prior total nephrectomy for primary renal cell carcinoma. Partial nephrectomy is allowed only if the resection margins were clearly negative 6. At least one measurable or non-measurable lesion (as per RECIST criteria) 7. Eastern Cooperative Oncology Group (ECOG) PS status 0-2 (Karnofsky Performance Status >70) 8. Good or intermediate prognosis disease as defined by Motzer score 9. Life expectancy 12 weeks 10. Adequate haematological function: - Absolute neutrophil count (ANC) >1.5 x 109/L AND - Platelet count >100 x 109/L AND - Haemoglobin >8 g/dL (may be obtained by the use of erythropoietin or transfusion for anaemia). 11. Adequate liver function: - Total bilirubin <1.5 x upper limit of normal (ULN) AND - Aspartate aminotransferase (AST), alanine aminotransferase (ALT) <2.5 x ULN in patients without liver metastases; <5 x ULN in patients with liver metastases 12. Adequate renal function: - Serum creatinine 1.5 x ULN AND - Urine dipstick for proteinuria <2+. Patients with >2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate <1 g of protein in 24 hours 13. International normalised ratio (INR) (in absence of anticoagulation treatment) >1.5 within 7 days prior to enrolment. Anticoagulation is allowed if target INR is < 3 and if the patient is on a stable dose of anticoagulant (coumarin type, low molecular weight heparin (LMHW) or bivalirudin or argatroban) for > 2 weeks at time of enrolment 14. Female patients should not be pregnant or breast-feeding. Women of child bearing potential (i.e. a woman who is biologically capable of becoming pregnant) must have a negative serum pregnancy test within 7 days prior to enrolment into the study. If a serum pregnancy test is not performed within 7 days prior to the first dose of bevacizumab, a confirmatory urine test (within 7 days prior to the first dose of bevacizumab) is required. Patients (men and women) must agree to use medically accepted contraceptive methods with their partners throughout the study and for 90 days after the last dose of study treatment (bevacizumab or IFN, whichever is administered last)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Prior systemic treatment for metastatic RCC disease (including neo-adjuvant therapy). Prior treatment with bevacizumab for any indication 2. Current or previously treated but non-stable (i.e. requiring changes in steroid dosage during the previous 4 weeks or receiving other therapy) central nervous system (CNS) metastases or spinal cord compression 3. Major surgery (incl. open biopsy) or radiation therapy within 28 days prior to enrolment. (Palliative radiotherapy to painful bone lesions is allowed within 14 days prior to enrolment). Subject must have recovered from prior surgery (> 28 days) and radiation (> 28 days - 14 days if palliative radiotherapy to painful bone lesions) 4. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to enrolment 5. Significant cardiovascular disease defined as congestive heart failure (NYHA Class II, III, or IV), unstable angina pectoris, or myocardial infarction within 6 months prior to enrolment 6. Inadequately controlled hypertension (defined as a blood pressure of > 150 mmHg systolic and/or > 100 mmHg diastolic on medication), or any prior history of hypertensive crisis or hypertensive encephalopathy 7. History of stroke or transient ischemic attack within 6 months prior to enrolment 8. Significant vascular disease (e.g., aortic aneurysm, aortic dissection), or symptomatic peripheral vascular disease 9. Evidence or history of recurrent thromboembolism (>1 episode of deep venous thrombosis / peripheral embolism) during the past 2 years, bleeding diathesis or coagulopathy 10. Chronic daily intake of aspirin >325 mg/day or clopidogrel >75 mg/day 11. History of abdominal or tracheo-oesophageal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrolment 12. Serious, non-healing wound, ulcer, or bone fracture 13. Immuno-compromised patients, including known seropositivity for human immunodeficiency virus (HIV) 14. Chronic treatment with corticosteroids (dose of >10 mg/day methylprednisolone equivalent) excluding inhaled steroids or substitution therapy 15. Known hypersensitivity to any component of the investigational drugs or excipients 16. Current active second malignancy other than non-melanoma skin cancers and post-treatment for localised prostate cancer. Patients are not considered to have a currently active malignancy if they are in complete remission for >3 years prior to study 17. Any other significant medical illness or medically significant abnormal laboratory finding that would, in the investigator?s judgment, make the patient inappropriate for this study, or would increase the risk associated with the patients? participation in the study 18. Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to enrolment
研究者
相似试验
进行中（未招募）
不适用
Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell carcinomaEUCTR2007-006611-23-LTF. Hoffmann-La Roche Ltd140
进行中（未招募）
不适用
Open-label, single-arm, phase II study of bevacizumab (AVASTIN®)in combination with low-dose interferon as first-line treatment ofnephrectomised patients with metastatic clear cell renal cell carcinoma - BEVLiEUCTR2007-006611-23-DEF. Hoffmann-La Roche Ltd140
进行中（未招募）
1 期
Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell carcinoma - BEVLIMetastatic renal cell carcinomaMedDRA version: 9.1 Level: LLT Classification code 10050513 Term: Metastatic renal cell carcinomaEUCTR2007-006611-23-GBF. Hoffmann-La Roche Ltd140
进行中（未招募）
不适用
Open-label, single-arm, phase II study of bevacizumab (AVASTIN) in combination with alternating Xeliri and Xelox as first-line treatment of patients with metastatic colorectal cancer - AXOAXImetastatic colorectal cancerEUCTR2011-003137-33-FIPia österlund and Helena Isoniemi100
进行中（未招募）
不适用
Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell carcinomaMetastatic renal cell carcinomaMedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaEUCTR2007-006611-23-FIF. Hoffmann-La Roche Ltd140